Caredx, Inc. · NASDAQ:CDNA
Caredx — 43rd Annual J.P. Morgan Healthcare Conference (January 2025)
23 slides from Caredx's conference presentation, Jan 14, 2025
Slide 1: The Transplant Solutions Company
The Transplant Solutions Company Click to edit Master title style Click to edit Master text styles •J A N U A R Y 1 4 , 2 0 2 5 Patrick G, Kidney Transplant Recipient
Slide 2: Safe Harbor Statement
Safe Harbor Statement These slides and the accompanying oral presentation contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of histor
Slide 3: Experienced Executive Leadership to Drive Profitable Growth
Experienced Executive Leadership to Drive Profitable Growth 650 CareDx Employees Globally 180 Commercial Employees John Hanna President & CEO Keith Kennedy Chief Operating Officer Jessica Meng Chief Commercial Officer Abhishek Jain Chief Financial Officer Headquartered in South Supporting our San Fr
Slide 4: CareDx is the Established Solutions Provider to Transplant Centers
CareDx is the Established Solutions Provider to Transplant Centers $50B Transplant Services Market ~1M Rejection Monitoring Tests Performed 70% Centers Use One Or More Software Products 46K Transplants Annually ~200K HLA Typing Kits Sold Annually 150K Rx Filled Annually by Transplant Pharmacy Source
Slide 5: CareDx Q4 2024 Preliminary Financial Highlights
CareDx Q4 2024 Preliminary Financial Highlights REVENUE TESTING VOLUME ADJUSTED EBITDA CASH BALANCE Q4 2024 $85-$86 ~45,500 $8-$9 $261 million million gain million YEAR- ~30% 14% ~$19 +$26 OVER-YEAR increase increase million gain million Please refer to GAAP to non-GAAP reconciliation for further de
Slide 6: Achieved Sixth Consecutive Quarter of Testing Services Volume Growth Across All Organs
Achieved Sixth Consecutive Quarter of Testing Services Volume Growth Across All Organs +14% +14% 49.9k 43.7k 44.6k 45.5k 39.9k 42.1k 37.5k 38.4k Q1 20231 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 1. Drop in Testing Services volume from Q1 2023 to Q2 2023 due to the impact of Billing Ar
Slide 7: Building Blocks of Growth
Building Blocks of Growth 4 PRODUCT PIPE LINE 3 PATI ENT ADHERENCE 2 CUSTO ME R ADOPTI ON 1 TRANSPL ANT VOLUME 7
Slide 8: Forces Driving Transplant Volume Growth
1 T R A NS P L A NT VO LU ME Forces Driving Transplant Volume Growth 11% Heart Transplant Annual Growth Growing government efforts are working to expand transplantation access 7% Kidney Transplant Annual Growth IOTA Model Increasing Organ Transplant Access Technological advances 12% are improving or
Slide 9: Synergistic Portfolio Drives Customer Adoption
2 CU STO M ER A DO P TI O N Synergistic Portfolio Drives Customer Adoption ORGAN MATCHING/WAIT LISTING CARE QUALITY/SYSTEM EFFICACY GRAFT HEALTH SOLUTIONS ACROSS PATIENT JOURNEY LAB PRODUCTS TRANSPLANT CENTER PATIENT DX & SOLUTIONS ▪ HLA Typing ▪ Transplant EMR ▪ Remote Monitoring ▪ Lab Management S
Slide 10: Multi-Solution Accounts Generate 2x Testing Services Revenue
2 CU STO M ER A DO P TI O N Multi-Solution Accounts Generate 2x Testing Services Revenue <3 SO LUTI O NS 29% $600K Average new transplant Average transplant center Accounts that have 3 or more patient acquisition for testing revenue from testing CareDx solutions have higher average patient acquisiti
Slide 11: Opportunity to Improve Patient Adherence
3 PAT I EN T A D H ER ENC E Opportunity to Improve Patient Adherence CURRENT PROTOCOL-DRIVEN number of tests/patient number of tests/patient in first 3 years in first 3 years 7 15 K ID NE YS 24 38 HE ART 10 20 L UN GS Sources: Protocol calculations based on: Heart HARTS protocol is11, 4, 4; Kidney A
Slide 12: Pipeline Fuels Additional Growth for Testing Services
4 P RO D UC T PI P EL I NE Pipeline Fuels Additional Growth for Testing Services 2 02 5 2 02 6 Expanded Indications AlloSure SPK AlloSure Heart PEDS AlloMap Kidney HistoMap Kidney UroMap Launch New Dx for use with Gene-expression profiling Diagnoses rejection Complements AlloSure AlloSure Kidney com
Slide 13: Evidence Strategy Drives Coverage Growth
Evidence Strategy Drives Coverage Growth B C BS FE D E R A L E MP LO Y E E S ~90% AlloMap Heart ~40% AlloSure Heart POLICY: Positive coverage for AlloSure Heart Covered Lives Covered Lives STUDY: HeartCare SHORE data, J Heart Lung Launched 2006 / Medicare Coverage 2006 Launched 2018 / Medicare Cover
Slide 14: Continuing to Build Evidence for Transplant Monitoring Assays
Continuing to Build Evidence for Transplant Monitoring Assays GENERATING EVIDEN CE PRIMARY STUDY STUDY COMPOSITION ▪ Pediatrics Validation ▪ >2,700 patients ▪ 5-year Survival SHORE ▪ 5-year follow-up HEA RT ▪ Directing Therapeutic Treatment ▪ 67 sites, HARTS protocol ▪ Procedure Decision Making ▪ >3
Slide 15: Charting a Path to Profitable Growth and Strategic Capital Allocation
Charting a Path to Profitable Growth and Strategic Capital Allocation 2027 FI NANCI AL TARG E TS 2025 GUI DANC E Profitable Growth Profits And Cash Revenue $500M 20% $370M 2027 Adjusted 2027 Revenue Target EBITDA Target +$100M 15% 3-Year Incremental Cash Target 3-Year Revenue CAGR Target Capital All
Slide 16: Building Blocks for Growth: Net Revenue
Building Blocks for Growth ~1% $500M ~3% PIPELINE AVERAGE SELLING 2027 ~7% PRICE (ASP) TOTAL CUSTOMER REVENUE ADOPTION & Net Revenue PATIENT ADHERENCE ~5% TRANSPLANT $332 - $333M PROCEDURES 2024 TOTAL REVENUE Source: 2024 preliminary financial results; CareDx internal targets. Data on file. Testing
Slide 17: Opportunities in Transplant-Adjacent Areas
Opportunities in Transplant-Adjacent Areas PRE-TRANSPLANT POST-TRANSPLANT Autoimmune Disorders Infectious Disease Solid Organ Transplant Cardiovascular Disease Cancer Cell Therapy Lung Disease Therapeutic Selection Hematology Disorders 17
Slide 18: Expanding Into Cell Therapy Monitoring
Expanding Into Cell Therapy Monitoring 5,600 Autologous and allogeneic cell therapy 70% Cancer (Blood and Solid Tumors) 10% Autoimmune Disorders 20% Other (e.g., Diabetes, Viral) registered clinical trials globally 220 Hematopoietic and bone marrow transplant Cell Transplant: Hematopoietic Stem Cell
Slide 19: Two Products Addressing Critical Unmet Need
Two Products Addressing Critical Unmet Need ALLOCELL MONITORS IMMUNE CELL THERAPY ALLOHEME DETECTS CANCER RELAPSE POST-CELL TRANSPLANT PHARMACOKINETICS Analyzes cells in blood Contraction Standard of Care SOC Relapse Detection Number of Cancer Cells % Cell Product Expansion Persistence Infusion 2 we
Slide 20: Activating Our Strategy
Activating Our Strategy PUT IN PLACE THE RIGHT TEAM IDENTIFIED THE MARKET OPPORTUNITIES LAUNCHING INNOVATIVE SOLUTIONS TO RESOLVE UNMET MEDICAL NEEDS 20
Slide 21: The Transplant Solutions Company
The Transplant Solutions Company CO NTAC T U S INVESTOR RELATIONS CORPORATE HQ Caroline Corner 8000 Marina Blvd, investor@caredx.com Brisbane, CA 94005 Click to edit Master title style MEDIA RELATIONS Click to edit Master text styles Anna Czene aczene@caredx.com Kristin J, Stem Cell and Double Lung
Slide 22: Appendix
Appendix » G CareDae | sooner a
Slide 23: Preliminary Reconciliation – Estimated GAAP Net Loss to Adjusted EBITDA Profit
Preliminary Reconciliation – Estimated GAAP Net Loss to Adjusted EBITDA Profit 23
CareDx — 43rd Annual J.P. Morgan Healthcare Conference (January 2025) on 6ix